Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Depot Buprenorphine (RBP-6000) Treatment Extension Study in Subjects With Opioid Use Disorder

NCT02896296 is registered in ClinicalTrials.gov with Indivior Inc. as lead sponsor.

NCT NCT02896296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02896296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Depot Buprenorphine (RBP-6000) Treatment Extension Study in Subjects With Opioid Use Disorder
Lead sponsor
Indivior Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 17, 2016
Completion date
August 23, 2017
Enrollment
208 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

opioid use disorder, opioid-related disorders